Protocols
4 protocol(s) meet the specified criteria
Drug: Atezolizumab
Protocol No.TitleStatus
GO29322A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients with Locally Advanced or Metastatic Solid TumorsOpen
GO29383A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB OR TAZEMETOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAOpen
WO30070A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based TherapyOpen
WO39210A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following NephrectomyOpen